癌症患者是否需要进行基因筛查以确定静脉血栓栓塞的可能性？

Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?

机构信息

Department of Biochemistry, Celal Bayar University School of Medicine, Manisa, Turkey.

出版信息

Med Princ Pract. 2012;21(2):160-3. doi: 10.1159/000333394. Epub 2011 Nov 5.

DOI:10.1159/000333394

PMID:22067726

Abstract

OBJECTIVE

To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients.

SUBJECTS AND METHODS

Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups.

RESULTS

Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk.

CONCLUSION

There is no possible benefit from genetic screening tests regarding VTE in cancer patients.

摘要

目的

确定与静脉血栓栓塞症（VTE）基因变异（FVL、FV H1299R、FII G20210A、MTHFR C677T、MTHFR A1298C、PAI-1 4G/5G、β-纤维蛋白原-455 G→A、FXIII Val34Leu 和 GpIIIa HPA-1a）相关的一些遗传多态性在癌症患者中的关联风险。